Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks.

Elmowafy, Mohammed; Ibrahim, Hany M; Ahmed, Mohammed A; Shalaby, Khaled; Salama, Ayman; Hefesha, Hossam

Elmowafy, Mohammed; Ibrahim, Hany M; Ahmed, Mohammed A; Shalaby, Khaled; Salama, Ayman; Hefesha, Hossam.

Afiliação

Elmowafy M; a Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy , Al-Azhar University , Cairo , Egypt.
Ibrahim HM; a Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy , Al-Azhar University , Cairo , Egypt.
Ahmed MA; b Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy , Cairo University , Cairo , Egypt.
Shalaby K; a Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy , Al-Azhar University , Cairo , Egypt.
Salama A; a Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy , Al-Azhar University , Cairo , Egypt.
Hefesha H; a Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy , Al-Azhar University , Cairo , Egypt.

Drug Deliv ; 24(1): 932-941, 2017 Nov.

Article em En | MEDLINE | ID: mdl-28617150

Assuntos

Nanoestruturas; Administração Oral; Animais; Atorvastatina; Portadores de Fármacos; Lipídeos; Tamanho da Partícula; Ratos

Palavras-chave

Atorvastatin; bioavailability; nanostructured lipid carriers (NLCs); oral delivery; pharmacodynamic effects

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanoestruturas Limite: Animals Idioma: En Revista: Drug Deliv Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google